Does Medicaid Cover Hormone Replacement Therapy? (2026)

Direct Answer

Yes, but it depends on why you need hormone therapy. Medicaid must cover FDA-approved HRT drugs for menopause and diagnosed hormone deficiency in every state because outpatient prescription drugs are a mandatory Medicaid benefit. Gender-affirming hormone therapy is different: about 20 states plus DC cover it for adults, roughly 27 states restrict or ban it, and an August 2026 CMS rule stops federal Medicaid and CHIP dollars from funding it for patients under 18.

What Medicaid Covers for Menopause and Hormone Deficiency

Outpatient prescription drugs are a mandatory Medicaid benefit in all 50 states and DC under the Medicaid Drug Rebate Program, established by Section 1927 of the Social Security Act. That means when a doctor prescribes an FDA-approved estrogen, progesterone, or testosterone product for a medically necessary reason such as moderate to severe menopause symptoms (hot flashes, vaginal atrophy, mood disturbances) or lab-confirmed hypogonadism, state Medicaid programs must cover it as a covered outpatient drug. Coverage can still come with a copay, typically $1 to $4 per prescription in most states.

State Medicaid formularies still control the details. A state can require step therapy (try a cheaper oral estrogen before approving a brand-name patch), place certain HRT products on a higher cost-sharing tier, or require prior authorization above a certain dose. New Jersey signed a law in January 2026 extending its full menopause coverage mandate, including hormonal and non-hormonal therapies and bone health screenings, to NJ FamilyCare (its Medicaid and CHIP program), effective April 2026, and other states are considering similar bills.

ACA-compliant marketplace plans handle HRT differently than Medicaid does. Marketplace plans must cover hormone therapy as part of the 10 essential health benefits when it treats a covered condition, but they use deductibles and coinsurance instead of Medicaid's low fixed copay, so someone who loses Medicaid eligibility and moves to a marketplace plan should expect a higher cost share for the same prescription.

Gender-Affirming Hormone Therapy: Where State Rules Diverge

Gender-affirming hormone therapy for transgender adults sits outside the federal drug mandate that guarantees menopause and hypogonadism HRT, so coverage is set almost entirely by state Medicaid policy. As of 2026, KFF tracks roughly 20 states plus DC that explicitly cover gender-affirming hormone therapy for Medicaid enrollees 18 and older, up against about 27 states that restrict or exclude it, a sharp jump from just 4 restrictive states in 2023.

In August 2026, CMS finalized a rule that blocks federal Medicaid and CHIP dollars from paying for cross-sex hormone therapy and puberty-suppressing medication prescribed to patients under 18 (under 19 for CHIP), effective October 13, 2026. Enrollees already receiving this treatment get a 6-month federal funding taper. The rule does not touch coverage for adults 18 and older or for non-hormonal mental health services, and states remain free to pay for youth gender-affirming hormone therapy entirely with state-only Medicaid dollars.

Cost Without Coverage in 2026

If a prior authorization is denied or a specific product is excluded from your state's formulary, the self-pay cost of hormone therapy in 2026 typically runs $15 to $50 a month for generic oral estrogen, $30 to $90 a month for transdermal estrogen patches, and $40 to $100 a month for injectable or gel testosterone at most retail pharmacies. Compounded bioidentical hormone preparations, which most Medicaid formularies exclude, commonly cost $100 to $300 a month out of pocket because they are not eligible for manufacturer rebates under the Medicaid Drug Rebate Program.

Prior Authorization, Formulary Tiers, and Common Denial Reasons

State Medicaid managed care plans commonly deny HRT claims for a handful of predictable reasons. Missing or outdated lab work is the most frequent one, since plans usually require documented hormone levels before approving testosterone or requiring a repeat estrogen dose increase. A second common reason is requesting a brand-name product before trying the generic or lower-cost formulary option under step therapy. A third is a diagnosis code that does not match an approved indication on the state's preferred drug list.

If your claim is denied, ask your prescriber to submit a written medical necessity letter citing your lab results and symptoms, and request the state's preferred drug list to see whether a covered alternative exists. Every state Medicaid denial comes with the right to appeal within 60 days, and you can request a state fair hearing if the internal appeal does not resolve it.

If You Have Medicare AND Medicaid (Dual-Eligible)

About 12 million Americans are dual-eligible for Original Medicare and Medicaid. For hormone therapy, Medicare Part D covers FDA-approved HRT drugs for menopause and hypogonadism through your plan's formulary, while Medicare Part B covers the office visit and lab work needed to diagnose and monitor hormone levels, subject to the standard Part D rules and any Medicare Advantage prescription drug plan's own tiering. Medicaid then wraps around Part D by covering the copay, drugs Part D excludes, and, in states that offer it, gender-affirming hormone therapy that Medicare does not distinguish as a separate benefit category. Medigap policies do not cover prescription drugs, so dual-eligibles rely on Part D plus Medicaid rather than a standalone Medigap add-on for HRT.

How to Get HRT Covered by Medicaid

Start by confirming your diagnosis is documented with lab results and clinical notes, since that is the single biggest driver of approval or denial. Then ask your provider or pharmacist to check your state Medicaid managed care plan's preferred drug list before the prescription is written, so you start with a formulary-preferred product rather than appealing a denial later. If your plan requires prior authorization, your prescriber submits the request directly; approval typically takes 1 to 14 business days depending on the state.

If you are seeking gender-affirming hormone therapy, call your state Medicaid office or check the KFF gender-affirming care policy tracker first, since coverage depends entirely on your state's current policy and, for enrollees under 18, on the October 2026 CMS funding rule. Medicaid.gov and your state's Medicaid member handbook list the current preferred drug list and prior authorization forms.

Does Medicaid cover hormone replacement therapy for menopause?

Yes. Every state Medicaid program must cover FDA-approved estrogen and progesterone products for medically necessary menopause symptoms under the mandatory Medicaid Drug Rebate Program. You may face step therapy or a formulary tier requirement, and copays typically run $1 to $4, but coverage itself is not optional for states.

Does Medicaid cover testosterone therapy for men?

Yes, when you have lab-confirmed hypogonadism (clinically low testosterone). Most state Medicaid plans require two confirmed low-testosterone lab results and prior authorization before approving injectable, gel, or patch testosterone. Testosterone prescribed without a diagnosed medical condition is not covered.

Does Medicaid cover hormone therapy for transgender people?

It depends on your state. About 20 states plus DC cover gender-affirming hormone therapy for transgender Medicaid enrollees 18 and older in 2026, while about 27 states restrict or exclude it. An August 2026 CMS rule additionally blocks federal Medicaid and CHIP funding for this therapy in patients under 18, effective October 13, 2026, though states can still pay with state-only funds.

What does HRT cost without Medicaid coverage in 2026?

Self-pay costs in 2026 typically run $15 to $50 a month for generic oral estrogen, $30 to $90 a month for estrogen patches, and $40 to $100 a month for testosterone injections or gel at most pharmacies. Compounded bioidentical hormones, which most state formularies exclude, often cost $100 to $300 a month out of pocket.

Does Medicaid cover bioidentical or compounded hormones?

Usually not. Most state Medicaid formularies limit coverage to FDA-approved, manufacturer-rebated products under the Medicaid Drug Rebate Program and exclude custom-compounded bioidentical preparations, which are not FDA-approved. Standard FDA-approved estrogen, progesterone, and testosterone products are covered instead.

Why did Medicaid deny my HRT prior authorization?

The most common reasons are missing or outdated lab results, requesting a brand-name product before trying a cheaper formulary alternative under step therapy, or a diagnosis code that does not match your state's approved indication list. Ask your prescriber to submit a written medical necessity letter and check your state's preferred drug list before reapplying.

Does Medicare cover HRT if I have both Medicare and Medicaid?

Yes. Medicare Part D covers FDA-approved HRT drugs for menopause and hypogonadism through your plan's formulary, and Medicaid then covers the copay and any drugs Part D excludes. About 12 million Americans are dual-eligible, and Medicaid also covers gender-affirming hormone therapy in states where it is a Medicaid benefit, since Medicare does not treat it as a separate covered category.

How do I appeal a Medicaid HRT coverage denial?

You have 60 days from the denial notice to file an internal appeal with your state Medicaid managed care plan, and you can request that benefits continue during the appeal in most states. If the internal appeal is unsuccessful, you can request a state fair hearing through your state Medicaid office, which is an independent review of the denial.